Skip to content

Role of Exosomes Derived From Epicardial Fat in Atrial Fibrillation

Role of Exosomes Derived From Epicardial Fat in Atrial Fibrillation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03478410
Enrollment
35
Registered
2018-03-27
Start date
2018-01-21
Completion date
2022-01-21
Last updated
2021-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

Epicardial fat

Brief summary

Exosome plays an important role in the pathophysiology of the cardiovascular system. Since the field of cardiovascular exosome is still in its infancy, there are no available data regarding to its role in cardiac arrhythmias. The current study investigates the role of epicardial fat derived exosomes in patients who suffer from atrial fibrillation.

Detailed description

Myocardial cells communication is mediated via direct cell to cell contact, cell to matrix interaction, long-range signals, electrical signals, and via extracellular chemical molecules (such as proteins, nucleotides, lipids and short peptides). Cell to cell communication can be achieved through direct contact (i.e. Gap junction, cell surface protein/protein interaction) or via secreted signaling molecules (i.e. hormones, neurotransmitters, cytokines). In the last few decades, a third intercellular communication mechanism has gained intense attention - extracellular vesicles that include: (1) apoptotic vesicles (1000-4000 nm), (2) microvesicles (100 nm - 1000 nm), and the smallest extracellular vesicles (3) exosomes (40-100 nm). The exosomes are produced through the endosomal pathway and are able to carry cargo and transfer them to recipient cells, thus contributing to cell-to-cell communication. The exosomes cargo includes protein content, rRNA, tRNA, short DNA sequences, messenger RNA (mRNA) and microRNA (miRNA). The last two can change the gene expression within the target cells and by that affect myocardial cells. Nowadays, it is known that in the cardiovascular system, exosome plays important roles in the pathophysiology of myocardial infarction (MI) and as an indicator for the damage and repair mechanisms post-acute MI (i.e. miR-126), in myocardial remodeling, and cardiac regeneration. Since the field of cardiovascular exosome is still in its infancy, there are no available data regarding to its role in cardiac arrhythmias. Therefore, there is place to investigate the role of exosomes in patients who suffer from atrial fibrillation. Some of the important issues to explore are: (1) Do the epicardial fat in patients with atrial fibrillation release quantitatively and qualitatively different exosomes than in patients without atrial fibrillation? (2) Can epicardial fat exosomes be a clinical biomarker for arrhythmias? (3) Can these exosomes be a target for the treatment and prevention of arrhythmias? The current study will include patients who undergo any cardiac surgery and will give informed consent. An epicardial fat biopsy will be taken and cultured in a medium that contain M-199 medium, dexamethasone, gentamicin, and insulin for 9 days. The exosomes will be collected from the medium and analyzed. The participants will be divided into two groups: (1) participants with atrial fibrillation, (2) participants who did not develop ever atrial fibrillation.

Interventions

PROCEDUREEpicardial fat biopsy

A 1 cm (\ 0.5 g) of epicardial pat biopsy from the area of the pulmonary artery

Sponsors

Sheba Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Intervention model description

Comparative study between patients with and without atrial fibrillation

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Undergoing an elective cardiac surgery

Exclusion criteria

* Undergoing a non-elective surgery * Suffering from severe renal impairment prior to surgery (creatinine clearance \<30 mL/min) * Experienced hepatic dysfunction other than mild

Design outcomes

Primary

MeasureTime frameDescription
Exosomes quantity excreted from the epicardial fat (nm)9 daysThe differences in the quantity of exosomes derived epicardial fat in patients with and without atrial fibrillation. The exosome isolation will be done by using ultra centrifuge for cells and cells debris removal. Then the exosomes will examined by the Malvern NanoSight device both for particle size and concentration measurement.

Secondary

MeasureTime frameDescription
Inflammatory cytokines secretion from epicardial fat9 daysThe differences in the Inflammatory cytokines secreted from epicardial fat in patients with and without atrial fibrillation. The investigators will detect the levels of cytokines and acute phase proteins such as IL1, IL2, IL6, IL8, IL10, IL12, CRP, VEGF, TNF-a, and TGF by Human Cytokine Array Kit.

Countries

Israel

Contacts

Primary ContactEilon Ram, MD
eilon.ram@sheba.health.gov.il972-54-4929101
Backup ContactDina Kogan
Diana.Kogan@sheba.health.gov.il972-52-8646402

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026